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Abstract
Background Medication errors and adverse drug events are
universal problems contributing to patient harm but the
magnitude of these problems in Africa remains unclear.
Objective The objective of this study was to systematically
investigate the literature on the extent of medication errors
and adverse drug events, and the factors contributing to
medication errors in African hospitals.
Methods We searched PubMed, MEDLINE, EMBASE,
Web of Science and Global Health databases from incep-
tion to 31 August, 2017 and hand searched the reference
lists of included studies. Original research studies of any
design published in English that investigated adverse drug
events and/or medication errors in any patient population in
the hospital setting in Africa were included. Descriptive
statistics including median and interquartile range were
presented.
Results Fifty-one studies were included; of these, 33
focused on medication errors, 15 on adverse drug events,
and three studies focused on medication errors and adverse
drug events. These studies were conducted in nine (of the
54) African countries. In any patient population, the med-
ian (interquartile range) percentage of patients reported to
have experienced any suspected adverse drug event at
hospital admission was 8.4% (4.5–20.1%), while adverse
drug events causing admission were reported in 2.8%
(0.7–6.4%) of patients but it was reported that a median of
43.5% (20.0–47.0%) of the adverse drug events were
deemed preventable. Similarly, the median mortality rate
attributed to adverse drug events was reported to be 0.1%
(interquartile range 0.0–0.3%). The most commonly
reported types of medication errors were prescribing errors,
occurring in a median of 57.4% (interquartile range
22.8–72.8%) of all prescriptions and a median of 15.5%
(interquartile range 7.5–50.6%) of the prescriptions eval-
uated had dosing problems. Major contributing factors for
medication errors reported in these studies were individual
practitioner factors (e.g. fatigue and inadequate knowl-
edge/training) and environmental factors, such as work-
place distraction and high workload.
Conclusion Medication errors in the African healthcare
setting are relatively common, and the impact of adverse
drug events is substantial but many are preventable. This
review supports the design and implementation of pre-
ventative strategies targeting the most likely contributing
factors.
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Key Points
This is the first literature review of African-based
studies that focuses on medication errors and adverse
drug events.
There have been limited reports on medication safety
in African countries in the past, but this is rapidly
increasing.
Of all patients admitted to hospital, a median of 2.8%
of adverse drug events resulted in hospital admission
in the general population, ranging to as high as 5.5%
in the adult population.
Regardless of the medication use process, dosing
problems were the most commonly reported type of
error.
1 Introduction
Quality patient care is a priority in all healthcare systems;
however, patient safety can be compromised leading to
potential medical harms [1]. Patient safety has been a
growing priority led by pioneer US studies: the Harvard
Medical Practice Study [2, 3] and the Institute of Medicine
Report [4]. In USA, it has been reported that 3.7% of all
hospitalised patients experienced an adverse event [2], and
preventable adverse drug events (ADEs) alone resulted in
7000 deaths annually [4]. Despite developments in
healthcare, these incidents continue to pose a significant
problem globally [5, 6] and remain a concern for con-
sumers, many practitioners and patient safety advocates.
Patient safety is a human rights issue and a subject
matter increasingly researched in many developed coun-
tries [7]. However, in the absence of comprehensive
healthcare coverage in the developing countries of Africa,
assuring patient safety remains a considerable challenge
when countries strive to provide quality patient care.
According to the United Nations [8], Africa consists of 54
fully recognised member states with a current population of
approximately 1 billion, and more than 40% of the popu-
lation in the sub-Saharan Africa is in extreme poverty [9].
The average health expenditure per person in sub-Saharan
Africa countries is below US$100 per annum compared
with US$6110 in Australia and US$9146 in USA [10].
Healthcare systems in Africa face severe health threats in
the context of scarce resources and underdeveloped
healthcare infrastructure, and the spectrum of patient safety
problems in this continent is unique in that most countries
lack integrated automated health systems to support patient
care [11].
Patient injuries attributed to medication misadventures,
including medication errors (MEs) and ADEs, are among
the most common incidents in hospitals [2] and have
important clinical, economic and social consequences. For
example, a review of Australian [12] medication safety
literature in 2003 showed that 2–4% of all hospital
admissions are thought to be medication related. An
updated review in 2009 [13] consistently reported a similar
burden of medication-related morbidity costing the Aus-
tralian healthcare system US$660 million annually. How-
ever, given the distinct nature of the morbidity profile and
drug utilisation pattern, and the level of awareness and
patient safety culture, the burden of medication-related
problems cannot be extrapolated for areas of poverty in
Africa [11].
While there have been many previous reviews of the
literature related to the burden of MEs and ADEs in the
hospital setting [14–23], most of these reviews have
included few or no African studies. There has been no
systematic review that broadly assessed the burden of MEs
and ADEs in African hospitals. Therefore, the aims of this
study were to review the available African-based literature
with a focus on: (1) the epidemiology of ADE-related
mortality and morbidity; (2) the causality, severity and
preventability of ADEs; (3) the magnitude and types of
MEs, and their clinical significance, and (4) the main fac-
tors reported to contribute to MEs in these studies.
2 Methods
2.1 Definitions
This study adopted the definition of ‘medication error’
approved by the National Coordinating Council for Medi-
cation Error Reporting and Prevention [24]: ‘‘a medication
error is any preventable event that may cause or lead to
inappropriate medication use or patient harm while the
medication is in the control of the health care professional,
patient or consumer’’. Medication errors can occur at any
stage of the medication use process, including product
labelling, packaging and monitoring. However, this study
specifically targets errors occurred at the ordering, tran-
scribing, dispensing and administration stages, and during
medication history taking. Various definitions pertaining to
each of the ME types are well documented in the interna-
tional literature [15, 17, 20, 21]. We, thus, solely classified
studies based on the stage of the medication use process in
which an error occurred. The definition of ADE employed
in this study was ‘‘any injury resulting from medical
2 A. B. Mekonnen et al.
interventions related to a drug,’’ and included both adverse
drug reactions (ADRs), in which harm occurs as a result of
the intrinsic nature of a medication, as well as complica-
tions from MEs [25]. The World Health Organization
(WHO) definition of ADR is ‘‘a response to a drug which is
noxious and unintended and which occurs at doses nor-
mally used in man for prophylaxis, diagnosis or therapy’’
[26]. An injury that is the result of ME is classified as a
preventable ADE whereas a non-preventable ADE (also
known as an ADR) is an injury other than an error, for
example, the occurrence of anaphylactic reactions in a
patient with no known previous history of a drug allergy
[25]. Another closely related terminology used in phar-
macovigilance and epidemiology studies is an adverse
event. It generally refers to an unintended injury occurring
during medical management, but which does not neces-
sarily have a causal relation to the drug, such as delayed or
improper diagnosis [1, 2].
2.2 Data Sources and Searches
This study used the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses guidelines in report-
ing the results [27]. A systematic literature search was
conducted using five electronic databases from inception to
31 August, 2017: PubMed (1946), MEDLINE (1946),
EMBASE (1966), Web of Science (1864) and Global
Health (1910). We categorised the search terms into three
key concepts and combined them using the AND Boolean
operator [Appendix S1 of the Electronic Supplementary
Material (ESM)]. No year of publication was imposed on
the search strategy but was limited to the English language.
In some databases, a database-specific limitation was
employed as in the Web of Science where article searching
was limited to the health sciences field, and abstract
availability was considered in the EMBASE and PubMed
databases. Additionally, articles were identified by hand
searching the bibliographies of included studies, and con-
tact with local medication safety experts was made to
identify other relevant published articles. One reviewer
(ABM) with the support of a medical librarian carried out
the literature search.
2.3 Study Selection
The lead author (ABM) screened the titles and abstracts of
retrieved studies and evaluated against the inclusion and
exclusion criteria. Selected abstracts then underwent full-
text screening. The full texts of studies that were poten-
tially eligible were evaluated by the same primary
reviewer, and then the final inclusion was agreed on by two
of the authors (AJM, JEB).
2.3.1 Inclusion Criteria
We included peer-reviewed original published articles,
irrespective of the study design, that investigated the fre-
quency and nature of MEs and/or ADEs. We did not set
any limitations on how ME types had been defined in the
original research studies. Similarly, the types of events
included were overlooked as far as the working definition
remained the same, such events range from ADRs to
ADEs. Studies that addressed adverse events were included
only if injuries due to medications were reported, and data
related to these were extracted. The primary outcome of
interest was the frequency of MEs (expressed in terms of
the number of prescriptions/medication orders/observations
with MEs of any type) and/or the proportion of patients
who experienced an ADE as a cause for admission or
occurred during hospitalisation. Secondary outcomes of
interest included an assessment of the nature of ADEs (e.g.
fatality and preventability) and MEs (e.g. clinical signifi-
cance). As we sought to evaluate the African medication
safety literature broadly, we also included studies that
assessed healthcare professionals’ experiences, possible
causes of MEs as reported by the original studies. We
placed no restriction on the target population, but studies
should be carried out in an African hospital setting.
2.3.2 Exclusion Criteria
Studies that investigated failures in optimising drug ther-
apy (e.g. drug dosage adjustment in patients with renal
failure), pharmaceutical issues (e.g. counterfeit or sub-s-
tandard medicines), events caused by single drugs or drug
classes (e.g. co-trimoxazole, Antiretrovirals) or disease
condition (e.g. human immunodeficiency virus/acquired
immunodeficiency syndrome, diabetes mellitus), and
studies that aimed to assess knowledge and attitude to ADR
reporting were excluded. In addition, studies evaluating
non-adherence to medication or self-harm (intentional
toxicity) were excluded. Conference abstracts, case studies,
commentaries and reviews were not considered in this
review.
2.4 Quality Assessment
While there are limited approaches for appraising obser-
vational studies of ADEs, we assessed such studies for their
quality. One review author (ABM) assessed all ADE
studies for their methodological quality based on the ten
criteria used by Smyth et al. [28]. The main domains
considered were study design, methods for identifying
ADEs, methods used to establish the causal relationship
between drug and effect, and tools for assessing the pre-
ventability and severity of ADEs. The quality of ME
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studies was evaluated and reviewed according to the 13
criteria adopted from the previous two studies [20, 29].
Criteria were graded as yes, no, unclear or not reported.
2.5 Data Extraction and Statistical Analysis
Data abstraction was performed using a standardised data
collection tool, which included study characteristics (pub-
lication details, African country, hospital setting, study
design, sample size and duration of the study, target pop-
ulation), identification of ADEs and/or MEs (definition,
method of data collection, information relating to assess-
ment of causality, severity and preventability) and major
findings (the frequency and clinical impact of MEs of any
type, prevalence data on ADEs causing admission and
occurring in the hospital, including clinical severity and
preventability). In studies presenting adverse event data,
only data for events due to medications (e.g. drug-related
complications and therapeutic errors) were extracted. The
most common factors contributing to MEs as reported by
the included studies were also extracted.
Adverse drug event studies were reported according to
the patient population (paediatric, all ages or adult), and the
types of MEs were stratified into sub-categories (pre-
scribing, administration, mixed). We used the term ADE
consistently; however, some of the studies provided ADR
data. The included studies were heterogeneous, and a meta-
analysis was not conducted. However, it was possible to
analyse the frequency of ADEs and MEs through calcula-
tion of the median occurrence rates and interquartile ranges
(IQRs) across studies. For ease of median (IQR) calcula-
tion and comparison across the studies, data extracted from




The literature search identified a total of 1316 citations,
which included 38 articles identified by hand searching
articles (Fig. 1). After removing duplicate citations, title
and abstract screening were applied on 1112 articles; of
which, 136 were selected for full-text review. Fifty-one
articles were finally identified for inclusion in the study
(Fig. 1). The most common reasons for excluding articles
after the full-text review were ADE prevalence data from
specific diseases and/or drugs or classes of drugs, and
studies that assessed knowledge and attitude of healthcare
professionals for ADR reporting (Appendix S2 of the
ESM). Of the 51 studies, 15 reported on ADEs [30–44], 33
reported on MEs (of any type) [45–77], and three studies
reported on ADEs and MEs [78–80]. The 51 studies were
from nine (of the 54) African countries: Nigeria (16), South
Africa (11), Ethiopia (9), Egypt (6), Morocco (3), Ghana
and Uganda (each 2), and Sudan and Tunisia (each 1)
(Fig. 2).
3.2 Characteristics of Adverse Drug Event Studies
Of the 18 included studies investigating ADEs, six were
conducted in South Africa and were published between
1979 and 2017. Eleven of the 18 studies were prospective
studies, and one was mixed (retrospective and prospective),
whereas the remainder were retrospective or cross-sec-
tional studies. A total number of 16,080 patients (excluding
mutual patients from Mouton et al. [40] study) were
evaluated for ADEs in these studies, mostly in the adult
patient population. Four studies [33, 41, 42, 79] clearly
reported ADE data for paediatric patients. Female patients
comprised 52.2% of the population (8097/16,080). Studies
varied in their duration from 5 days to 3 years, and most
studies [30, 32, 36, 38–40, 44] were exclusively conducted
in the general medical wards (Table 1).
3.2.1 Quality Assessment of Adverse Drug Event Studies
Using the assessment criteria adopted from Smyth et al.
[28], the quality of ADE studies was evaluated. Four
studies [33, 34, 40, 42] met all the ten criteria (Appendix
S3 of the ESM). All included ADE studies clearly defined
their study design. A variety of methods were used to
detect ADEs. The most common method was medical
record review [30, 33–40, 44, 79, 80]. Ten studies
[33, 34, 36, 39, 40, 42, 44, 78–80] used a multifaceted
approach for identification of ADEs: a medical record
review in combination with other methods, such as vol-
untary reports, participation in clinical rounds,
patient/carrier interview and prescription/laboratory data
review. The reported assessment of ADEs with respect to
causality, severity and preventability varied among the
studies. Causality assessment was described in 15 studies,
mostly using the WHO definition [85, 88] (four studies).
Severity was measured in 13 studies, mostly using the
WHO criteria [82] (three studies) and the same number of
studies assessed preventability, predominantly using the
Schumock and Thornton method [83] (eight studies)
(Table 1). All but three studies [30, 32, 36] provided
information about the person responsible for the investi-
gation of the initial ADE detection. Usually a team of
physicians, nurses and pharmacists was involved. Verifi-
cation of the identified ADEs was addressed in eight
studies [33–35, 37–41]. The WHO definition [26, 89] of
ADRs had been adopted in the majority of studies
[31, 34, 38, 41, 42, 44], but two studies [30, 36] did not
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explicitly state the description of an incident (Appendix S4
of the ESM).
3.2.2 Frequency and Nature of Adverse Drug Events
3.2.2.1 Adverse Drug Events Causing Hospital Admis-
sions A total of 11 studies [30–33, 36, 38, 40–44]
involving 12,903 patients reported the number of patients
for which an ADE was the primary reason for hospitali-
sation. Of these studies, three targeted the paediatric pop-
ulation only [33, 41, 42]. In any patient population, the
percentage of patients who were admitted as a direct cause
of ADEs and not another condition, varied from 0.4% [41]
to 14.3% [43]. The overall median ADE prevalence
showed that 2.8% (IQR: 0.7–6.4%) of patients were
admitted in African hospitals as a result of ADEs (Table 2).




Full-text articles assessed for eligibility
(n=136)
Medication errors (MEs) (n=33) Adverse drug events (n=15)
Articles identified from database 
searching 
(n=1,278)
Additional articles identified through 
hand-searching 
(n=38)
Records after duplicates removed 
(n=1,112)
Mixed (MEs, ADEs) (n=3)
Articles excluded 
(n=976)
Articles excluded, with 
reasons   (n=85)
ADE/ADRs reports from 
single disease/agents = 27
ADR reporting = 18
Non relevant outcome = 17


























Fig. 1 Preferred reporting
items for systematic reviews
and meta-analyses flow diagram
of the selection of eligible



































Fig. 2 Graph showing origin of
included studies. * one study
from Ethiopia and two studies
from Morocco gave data for
both adverse drug events
(ADEs) and medication errors
(MEs), and counted as
independent studies in this
figure
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After the exclusion of studies that reported data on the
paediatric population only, the median prevalence estimate
was found to be 5.5% (IQR: 1.8–8.0%).
3.2.2.2 Any Suspected Adverse Drug Events at Hospital
Admission Three studies [38, 43, 44] estimated the per-
centage of patients experiencing any ADEs, which may or
may not be the cause for hospitalisation, at the time of
hospital admission. Of the total 1900 patients evaluated for
any suspected ADEs at hospital admission, at least one
ADE was identified in 192 patients, and the overall median
prevalence of any suspected ADEs in these studies was
8.4% (IQR: 4.5–20.1%) (Table 2).
3.2.2.3 Adverse Drug Events during Hospitalisation No
separate ADE data were reported in one study [35]; the aim
was not primarily an assessment of ADEs. Fourteen studies
[30, 31, 33–38, 41, 42, 44, 78–80] reported the occurrence
of ADEs during hospitalisation. The percentage of patients
who developed at least one ADE during a hospital stay
ranged from 0.7% [41] to 49.5% [44], with an overall
median incidence of 7.5% (IQR: 3.8–12.8%) (Table 2).
After the exclusion of studies carried out solely on the
paediatric population, the median percentage for this out-
come was reported to be 10.7% (IQR: 4.3–16.1%).
3.2.3 Severity and Seriousness of Adverse Drug Events
Thirteen studies [31, 33–35, 37, 38, 40–42, 44, 78–80]
assessed the seriousness and/or severity of an ADE; how-
ever, data for two studies [35, 37] were not available as
ADE-specific data were not provided. Assessment of
clinical severity varied among the included studies, and
one study [34] clearly made a distinction between severity
and seriousness measurement, and two studies [41, 42]
reported the severity of ADEs only. Many studies (9/13)
reported the seriousness of ADEs, but this was also
assessed variably, and thus, for ease of analysis, we broadly
classified serious ADEs (like Symth et al. [28] did) as those
that caused either death or were life threatening, resulted in
Table 2 Frequency, seriousness and preventability of adverse drug events (ADEs) in African hospitals



















Benkirane, 2009 [31] 1.4 4.2 47.5 0.1 13.2
Benkirane, 2009 [78] 11.5 51.8 0.3 30.0
Cooke, 1985 [32] 4.6
Eshetie, 2015 [33] 0.7a 7.7a 9.0 0.2 33.0
Dedefo, 2016 [79] 7.3 5.9 0.0 47.0
Jennane, 2011 [80] 12.7 87.5 3.2
Kigbua, 2017 [34] 25.0 31.0 0.0 55.0
Letaief, 2010 [35] 2.7a NS NS NS
Mabadeje, 1979 [36] 2.8 13.1
Matsaseng, 2005 [37] 9.8a NS NS NS
Mehta, 2008 [38] 6.3 6.3 8.4 50.4a 0.3a 46.0
Mouton, 2015 [39] 2.9 43.5
Mouton, 2016 [40] 8.5a 23.5 d 45.0
Oshikoya, 2007 [41] 0.4 0.7 SG 0.1 97.7
Oshikoya, 2011 [42] 0.6 1.1 SG 0.1 20.0
Tipping, 2006 [43] 14.3a 20.1
Tumwikirize, 2011 [44] 1.5 49.5 4.5 0.0 0.0 4.1
Median (IQR) 2.8 (0.7–6.4) 7.5 (4.3–16.1) 8.4 (4.5–20.1) 23.5 (9.0–50.0) 0.1 (0.0–0.3) 43.5 (20.0–47.0)
IQR interquartile range, NS no specific data available, SG only severity grading reported
a Not provided directly in the study, interpreted from other presented data
b The total number of patients was used as a denominator in the respective studies
c The total number of reported ADEs was used as a denominator in the respective studies
d Mortality data from the Mouton et al. study [40] were already used in the calculation of the mortality rate by their previous study [39] and are
not presented here
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permanent disability or hospital admission or prolonged
hospitalisation. Of the 9 studies, one study [44] did not
report serious events during admission and/or hospitalisa-
tion, and the remainder included serious ADEs of various
rates: 5.9% [79] to 87.5% [80] of all ADEs. The median
proportion of serious ADEs reported by all the nine studies
was 31.0% (IQR: 7.5–51.1%) of all ADEs (Table 2). The
median occurrence of serious ADEs, when paediatric-only
studies were excluded, was found to be 47.5% (IQR:
23.5–51.8%).
Only one study from South Africa [39] entirely focused
on mortality associated with ADRs, investigating the pro-
portion of deaths attributed to ADRs in medical in-patients
at four hospitals through a review of medical notes, medi-
cation exposure (during the previous 30 days) and labora-
tory data. This study estimated that ADEs contributed to the
death of 2.9% of hospital admissions, and 16% of all hos-
pital deaths were attributed to ADEs [39]. In the remainder
of studies, the mortality rate associated with ADEs was
reported as a secondary outcome of interest. In general, no
fatal ADEs were reported in three studies [34, 44, 79], and
nine studies [31, 33, 38–42, 78, 80] reported fatal ADEs in
68 of 12,866 patients included in the analysis. In the general
population, the median mortality rate attributed to ADEs
was estimated to be 0.1% (IQR: 0.0–0.3%) (Table 2).
However, when the paediatric data were excluded, deaths
associated with ADEs was reported in a median of 0.3%
(IQR: 0.0–2.9%) of all patients.
3.2.4 Preventability of Adverse Drug Events
Thirteen studies [31, 33–35, 37–42, 44, 78, 79] performed a
preventability assessment for ADEs describing a variable
preventability of 4% [44] to 97.7% [41] of all events.
However, data for Letaief et al. [35] and Matsaseng and
Moodley [37] were not available as ADE-specific data
could not be extracted, but showed a preventability of 60
and 55%, respectively, in the overall incidence of adverse
events. The median percentage of preventable ADEs
reported by all the remaining 11 studies was 43.5% (IQR:
20.0–47.0%) of all ADEs (Table 2).
3.3 Characteristics of Medication Error Studies
Of all the 36 ME studies (including those evaluated both
MEs and ADEs), ten studies did not specify the type of
MEs; 14 studies evaluated medication administration errors
and 12 studies assessed prescribing errors. No studies were
identified that specifically reported transcribing errors,
dispensing errors and medication history errors. Most
studies (12/36) were conducted in Nigeria and 8 studies
[55, 60, 62, 67–69, 74, 78] were conducted in a multicentre
setting. Five studies [50, 52, 56, 65, 79] were solely
conducted in a paediatric ward and one study [73] in an
obstetric ward. Two pre-post studies were identified
[49, 50], and the remaining were either observational
studies (prospective or retrospective) or quantitative/qual-
itative surveys. Of these, eight questionnaire-based studies
and two mixed-method studies were identified (six
administration errors, three prescribing errors, one mixed
error) to evaluate MEs reported by various healthcare
professionals (Table 3).
3.3.1 Quality Assessment of Medication Error Studies
After the application of the quality assessment criteria
against ME studies, criteria appropriate for any ME study,
no study met all the 13 criteria. One study (each) fulfilled
12 and ten criteria, 2 studies met 9 criteria and 8 studies
met eight criteria. The remaining studies met seven or
fewer criteria (Appendix S3 of the ESM). The type of MEs
was not specified in ten studies, and various definitions for
ME were used in the included studies (Appendix S4 of the
ESM). Eleven studies did not describe adequate details of
MEs, and studies differed in methods for identifying MEs.
The majority of the studies employed a prescription review
(to identify prescribing errors) and observations (for
assessing medication administration errors) but one study
[61] did not explicitly report the method of error detection
(Table 3).
3.3.2 Frequency and Nature of Medication Errors
3.3.2.1 Medication Errors (Mixed) All but one study
[74] that assessed MEs of any type were able to report
details of the error rate. However, these data were difficult
to summarise as error rates were presented in different
ways. For example, MEs were reported in 75% [79] to 97%
of patients [76], 10–54.8% of medication orders [72, 80],
4.2% of prescriptions [73] and 2.9% of medication doses
[75]. Additionally, the incidence of MEs were reported in
7.5–7.8 per 100 admissions [78, 80], 7.7–9.7 per 1000
patient-days [78, 80] and 40.5 per 100 person-years [71].
Six studies [73, 75, 77–80] explicitly described the stage at
which errors were occurred in the medication use process.
Most errors were identified during prescribing, median
(IQR): 41.3% (26.8–58.3%) [73, 75, 77–80] followed by
the administration stage, median (IQR): 20.6%
(12.5–41.6%) [73, 75, 77–80] and then the monitoring
stage, median (range) 16.7% (8.4–25.0%) [77, 79].
3.3.2.2 Prescribing Errors Studies that addressed pre-
scribing errors reported a median error rate of 57.4% (IQR:
22.8–72.8%) of all prescriptions [45, 51, 52, 54] and 40.0%
(IQR: 8.8–49.5%) of medication orders [46, 49, 53, 54, 56]
(Fig. 3).
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3.3.2.3 Medication Administration Errors Eight studies
[57–59, 61, 62, 65, 66, 68] calculated medication admin-
istration error rate. A study by Amucheazi and Ajuzieogu
[61] analysed only a single component of the medication
administration procedure in an anaesthetic department,
with incorrect drug administration reported in 0.5% of
elective surgical procedures. A study by Llewellyn et al.
[68] has reported an administration error incidence of one
in 274 anesthetics administered. These events were further
consolidated from self-reports [60, 63, 64, 67, 69] showing
that 39–94% of doctors/anaesthetists/physician assistants
reported at least one medication administration error in
their career. Other than anaesthetic administration errors,
one questionnaire-based study [70] of a paediatric nurse’s
experience of medication administration errors reported
that 64% of nurses described at least one error over the
course of their career. Overall, at least one medication
administration error has been reported in a median of
56.4% (IQR: 39.5–87.5%) of all medication administration
observations [57–59, 65, 66].
3.3.3 Types of Medication Errors
The most common type of errors reported in the reviewed
studies was greatly influenced by the methodological
approach, and there were also various classifications of
error types depending on the medication use process. In
general, all but five studies [47, 55, 61, 64, 67] included
some details regarding the most common types of errors in
their report. Of these, 29 of the 31 studies identified the
type of MEs reported commonly and was a prescription
and/or an administration for an incorrect dose. Other
commonly reported errors included wrong drug combina-
tion and/or selection (21/31), wrong route of administration
(17/31), omission errors (15/31) and wrong frequency and/











































































































































































































































































































































































































































































































































































































































































































































































































Prescribing error rate, %
Fig. 3 Graph showing the extent of the prescribing error rate in
African hospitals. Light bars indicate total medication orders used as
denominators for error calculation. Solid bars indicate total prescrip-
tions used as denominators for error calculation





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































16 A. B. Mekonnen et al.
Specifically, error rates among the studies were greatly
affected by the definitions pertaining to MEs (of any type).
In studies with a broader error definition, including the
completeness of a prescription (e.g. dosage form, age of a
patient, legalisation of the prescription), a higher error of
this type was reported in the respective studies. Negash
et al. [72], for example, have shown that there were no
medication orders described on the dosage form on the
prescription. Similarly, other studies [47, 51, 54, 56] also
reported the provision of incomplete prescribing informa-
tion (incomplete description of prescription items, omis-
sion of duration, legality of prescription) in 52–86% of all
prescriptions. This review revealed that MEs of any type
associated with dosing problems have been shown in a
median of 14.2% (IQR: 7.8–21.7%) of all errors. Specifi-
cally, a median of 15.5% (IQR: 7.5–50.6%) of the pre-
scriptions and 3.4% (IQR: 1.5–7.9%) of the medication
orders, and 16.6% (IQR: 1.9–27.4%) of the medication
administration observations were reported to contain dos-
ing errors (Fig. 4).
3.3.4 Clinical Significance of Medication Errors
Most of the studies did not investigate the clinical impact
of the reported MEs. Excluding those studies that measured
consequences of MEs through self-reports, 11 studies
addressed the impact of MEs [46, 50, 53–55, 57,
59, 77–80]. However, these studies varied in terms of
measuring tools for the clinical significance of errors. Of
all the MEs collated, only four fatal errors from three
studies [57, 78, 80] were reported, and in six studies
[46, 53, 54, 57, 78, 80], the median percentage of clinically
serious MEs (defined as errors with a potential to cause
death, and were life threatening or resulted in permanent
disability or prolonged hospitalisation [28]) were identified
in 5.1% (IQR: 1.7–29.2%) of MEs. Data from self-reports
[63, 67–69] also showed that most of the errors committed
by healthcare professionals were trivial and would not have
resulted in deaths.
3.4 Factors Contributing to Medication Errors
Investigating the factors that contributed to MEs was the
focus of 15 studies [47, 48, 55, 57, 60, 63, 64, 67, 69,
70, 74, 75, 77–79]. Only one qualitative study [47] using
human error theory uncovered the causes of prescribing
errors committed by junior medical doctors in an in-patient
setting. In contrast, 9 of the 15 studies [48, 55, 60,
63, 64, 67, 69, 70, 74] employed self-report data to assess
the possible causes of MEs as a whole, causation data from
four studies [57, 75, 77, 78] were based on individual
errors, and it was not clear how these data were collected in
one study [79]. The factors most commonly cited as con-
tributory to MEs were individual factors (e.g. fatigue and
inadequate knowledge/training), working environment
(e.g. distraction and high workload) and task (e.g. look-
alike names and labelling deficits) (Table 5).
4 Discussion
4.1 Main Findings
This is the first systematic review of the burden and nature
of MEs and ADEs in African hospitals. This study was able
to identify 51 studies in nine African countries; of these, 18
assessed ADEs. In any patient population, the median
prevalence of any suspected ADE on hospital admission
(that could likely or unlikely lead to admission/hospitali-
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Dosing error rate, %Fig. 4 Graph illustrating the
percentage of prescriptions or
medication orders or medication
administrations with dosing
errors in African hospitals.
Light bars indicate the study
used the total number of
medication orders as a
denominator to calculate dosing
errors. Solid bars indicate the
total number of prescriptions
































































































































































































































































































































































































































































































































































































































18 A. B. Mekonnen et al.
admitted as a direct cause of ADEs. Adverse-drug event-
related fatalities were relatively uncommon but the rate
varied across the studies considerably, and it was reported
that close to 44% of the ADEs were deemed preventable. It
was reported that the rate of MEs was high, and most
commonly occurred at the stage of prescribing. Dosing
errors have been frequently reported; however, many of the
errors were clinically insignificant. A range of factors
contributing to MEs has been described in African hospi-
tals including fatigue, lack of knowledge and training, high
workload and workplace distraction.
4.2 Comparison with Existing Literature
There is a lack of high-quality studies with rigorous
designs that investigate medication safety in African hos-
pitals. In fact, the study of MEs can be considered a rela-
tively new area of research as studies have only emerged
since 2004 [63], although research on outcomes from
ADEs dates back to the 1970s [36].
Although there was a wider variation in the definition,
method of detection and assessment, this review has
shown that African hospitals reported a higher rate of
MEs than similar reviews conducted on data mainly from
developed countries [15–17] but was consistent with
other reviews from the Middle East [20, 21] and South-
east Asia [29]. In the present study, the majority of the
studies evaluated medication administration errors; how-
ever, the prescribing stage is the stage at which the
highest error rate occurred in African hospitals. Other
reviews have also demonstrated that prescribing errors
were the most common MEs to occur in the hospital
setting [17, 20]. However, a review of the extent of MEs
in Iran reported that medication administration errors
were the most commonly reported types of errors [21].
This difference may be owing to the high number of
studies that evaluated medication administration errors in
that review (83% of the studies). A previous systematic
review [20] from Middle Eastern countries reported an
incidence of prescribing errors in 7.1–90.5% of pre-
scriptions, which is comparable to the present study
examining African hospitals. However, a review [17] of
studies from USA or the UK (72% of the studies)
reported a lower rate of prescribing errors (2–14%).
Similarly, the rate of administration errors in this study is
comparable to that from Middle Eastern countries
(9.4–80%) [20, 21] and Southeast Asia (15.2–88.6%) [29]
but higher than that reported from developed countries
(8.6–28.3%) [15].
In the present study of medication administration errors,
the surgical/anaesthetic department has shown a different
pattern in terms of the frequency and nature of incidents
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administration procedure; that is, wrong medication
administration with an emphasis on anesthetic medications
only were reported, and much of the concern was because
of a syringe swap or syringe/drug misidentification of
anaesthetics. A lower incidence of MEs in anaesthesia was
reported, and this may be expected and consistent with
other studies [99, 100], as this may be considered a rela-
tively safe environment, but still over two thirds of doctors/
anaesthetists/physician assistants reported making at least
one error during their career.
Regardless of the medication use process, dosing prob-
lems were the most commonly reported types of errors,
which is supported by previous reviews [20, 21]. This study
has identified most errors were clinically insignificant. In
the extreme, there were also medication-related fatalities
not reported in previous reviews [15, 20, 21] or reports
from developed countries [101, 102]. However, the
prevalence of ADE-related admission aligns with data from
the international literature [12, 13, 22, 23]. For example, a
systematic review of European studies [23] has identified
individual studies with the highest fatal ADRs in 0.49% of
all patients admitted because of ADRs, which is lower than
that reported in our review (2.9%). Unlike the pattern in
developed countries, a larger proportion of ADE-related
deaths in Africa is mostly the result of medications used in
the treatment of human immunodeficiency virus and
tuberculosis [38, 39], also reflecting the high burden of
these diseases in the African hospital setting.
Many systematic reviews have estimated the proportion
of patient admissions attributable to ADEs to range
between 2 and 5.3% [12, 13, 22, 23, 28]. Our median ADE
estimate for ADEs that occurred during hospitalisation is
close (only when the paediatric studies were excluded) to
an estimate from another systematic review of ADRs in the
elderly, which has reported an ADR prevalence of 11.5%
[103]. Our finding that many of the ADEs were deemed
preventable is in line with a systematic review by Hak-
karainen et al. [104], which estimated that 52 and 45% of
the ADEs are preventable in the adult outpatient and
inpatient settings, respectively. This highlighted the
importance of designing appropriate prevention strategies
for the best possible reduction in medication-related harms.
4.3 Strengths and Limitations
The main strength of this study was the exploration of
the medication safety literature with broader inclusion
criteria (consisting of ADEs and MEs) across a range of
hospital settings in Africa. No limit on the year of pub-
lication was applied, and also an extensive search of
articles was done. For example, our study identified
studies that were not included in previous systematic
reviews, such as in the Leendertse et al. study [105],
which includes only one African study. Furthermore, our
search strategy was able to identify many relevant studies
not previously located.
However, the strengths of the results and evidence base
presented in this review depend on the strength of data
collected from the individual study. For instance, validity
and reliability of ADE detection were infrequently repor-
ted, and the majority of studies relied on an initial single
screening phase without further verification from an inde-
pendent review. Studies often lacked a valid assessment
tool to help establish causality between medication
misadventures/harms and the offending agent, and the
same for preventability and severity. There were also
heterogeneities among the included studies with regard to
the methods used to detect ADEs and their definition,
which may be one of the reasons for a wide range of
individual estimates. Over half of the studies did not pro-
vide a working definition of a ME nor described compo-
nents of a ME. Additionally, different definitions of a ME
were used among the studies, and there was variability in
the typology of MEs, for example, some studies excluded
dosage form errors, illegibility and legalisation of the
prescription. There was also a wide variation in the
methods of data collection, and inconsistencies in ME
assessment and reporting, leading to difficulties in esti-
mating the rate of MEs.
We did not perform a thematic analysis for causes of
errors in this study. This was because there was hetero-
geneity in the way studies reported these data, and
mainly the data were extracted from questionnaire-based
studies. There was only one study that used a human
error theory for explaining error causes, and for ease of
simplicity, we summarised error causes as individual,
work environment, team and task factors. Furthermore,
the quality of these studies was judged grossly and not on
an outcome basis. Another potential limitation of this
study is the restriction of the search to published litera-
ture and English language. Limiting the search to the
English language might contribute to our few included
studies; notably, publications from French-speaking
countries might delimit the number of articles included in
the present study. Apart from language, the African
content is characterised by a diverse geographical area
and thus, caution should be taken in the interpretation of
our findings. It should also be noted that the scanning of
titles and abstracts of the search results was performed by
a single researcher. However, our review was compre-
hensive and because there has been no published review
addressing these issues in Africa, this review sheds light
on the extent of MEs and their associated harms in the
African hospital setting.
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4.4 Implications for Future Research
This review highlights that African hospitals share much of
the challenges in the medication safety literature observed
across the globe. A challenge in reviewing these studies is
that, there is no universally accepted method for either
causality assessment of ADEs [106] or estimation of its
preventability [107], nor a denominator for error rate
reporting [108] and a tool for severity measurement [109].
However, when designing patient safety programmes
specifically targeting MEs and their misadventure, it is
essential that future studies should assess the causality,
preventability and clinical consequences associated with
them. More importantly, the effectiveness of medication
safety programmes designed to reduce errors requires these
tools for complete evaluation. Unfortunately, in our review,
only two pre-post studies were retrieved that aimed to
decrease the frequency of prescribing errors.
In countries with better resources, medication safety
programmes are well integrated with the healthcare system
[110, 111]. In developing countries like many in Africa,
however, healthcare coverage is prioritised to medication
safety, and the medication use system is not evidence based
[33]. However, the medical community believes in the
need to implement strategies to protect patients from
medication harms. This warrants interventional pro-
grammes to be tested despite the resource limitations. Of
the various strategies, adoption of electronic prescribing
[110] and greater targeted involvement of pharmacists
[111–113] in care teams are documented internationally.
Currently, there is also an influx of information technology
in the African healthcare system [114], and an extension of
a pharmacist’s role in patient care [115], which could lead
to a momentous change in medication safety programme
implementation. Furthermore, individual factors, such as
knowledge deficits, were described as a major contributing
factor for medication incidents; thus, educational sessions
may be essential as a preventive strategy and should be
evaluated in future studies. No studies that specifically
assessed transcribing errors, dispensing errors and docu-
mentation errors in African hospitals were retrieved.
5 Conclusion
This review has found that there have been limited reports
on medication safety in African countries in the past, but
this is increasing over time. There is, however, a lack of
high-quality studies with rigorous designs that investigate
the frequency and nature of MEs and ADEs. Based on the
current literature, ADEs are an important cause of mor-
bidity in African hospitals, both on admission and during
hospitalisation, but many are deemed preventable.
Medication errors are common and mostly occur at the
prescribing stage. Dosing errors are frequently reported,
but many of the reported errors are clinically trivial. There
is a paucity of information on other types of errors, such as
dispensing, transcribing and documentation errors.
Designing preventive strategies to target the most likely
contributing factors is of paramount importance.
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